Phase II study of pemetrexed in combination with cisplatin in patients with advanced urothelial cancer: the PECULIAR study (KCSG 10-17)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi, Y. J. | - |
dc.contributor.author | Lee, S. H. | - |
dc.contributor.author | Lee, J-L | - |
dc.contributor.author | Ahn, J-H | - |
dc.contributor.author | Lee, K-H | - |
dc.contributor.author | You, D. | - |
dc.contributor.author | Hong, B. | - |
dc.contributor.author | Hong, J. H. | - |
dc.contributor.author | Ahn, H. | - |
dc.date.accessioned | 2021-09-04T20:00:30Z | - |
dc.date.available | 2021-09-04T20:00:30Z | - |
dc.date.created | 2021-06-15 | - |
dc.date.issued | 2015-01-20 | - |
dc.identifier.issn | 0007-0920 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/94624 | - |
dc.description.abstract | Background: Pemetrexed has shown a favourable response rate of about 30% with minimal toxicity when used as a single agent for treatment of advanced urothelial carcinoma. This phase II study evaluated the efficacy and safety of pemetrexed plus cisplatin in advanced urothelial carcinoma. Methods: This multicentre, single-arm, open-label, phase II clinical trial enrolled patients who had advanced urothelial carcinoma, ECOG PS 0-2, and measurable disease. Pemetrexed 500 mg m(-2) with cisplatin 70 mg m(-2) on day 1 were administered every 3 weeks. The primary endpoint was the objective response rate (ORR). Secondary endpoints were progression-free survival (PFS), overall survival (OS), and toxicity. Results: A total of 42 patients were enrolled (median age, 66 years; ECOG 0-1, 100%; visceral metastasis, 54.8%; recurrent disease, 57.1%). Twenty-seven partial responses for an ORR of 64.3% (95% CI, 49.2%-77.0%) were documented. Seven patients had stable disease. Median PFS and OS were 6.9 (95% CI, 6.2-7.6) and 14.4 (95% CI, 10.4-18.4) months, respectively. Grade 3 or 4 neutropenia was observed in 28.6% of patients. No patients experienced febrile neutropenia. Conclusion: The combination of pemetrexed and cisplatin is active, and well tolerated in patients with advanced urothelial cancer as a first-line treatment. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SPRINGERNATURE | - |
dc.subject | TRANSITIONAL-CELL CARCINOMA | - |
dc.subject | COLONY-STIMULATING FACTOR | - |
dc.subject | THYMIDYLATE SYNTHASE | - |
dc.subject | PLUS GEMCITABINE | - |
dc.subject | G-CSF | - |
dc.subject | CHEMOTHERAPY | - |
dc.subject | TRIAL | - |
dc.subject | METHOTREXATE | - |
dc.subject | MULTICENTER | - |
dc.subject | CARBOPLATIN | - |
dc.title | Phase II study of pemetrexed in combination with cisplatin in patients with advanced urothelial cancer: the PECULIAR study (KCSG 10-17) | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Choi, Y. J. | - |
dc.identifier.doi | 10.1038/bjc.2014.591 | - |
dc.identifier.scopusid | 2-s2.0-84922337376 | - |
dc.identifier.wosid | 000348281100006 | - |
dc.identifier.bibliographicCitation | BRITISH JOURNAL OF CANCER, v.112, no.2, pp.260 - 265 | - |
dc.relation.isPartOf | BRITISH JOURNAL OF CANCER | - |
dc.citation.title | BRITISH JOURNAL OF CANCER | - |
dc.citation.volume | 112 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 260 | - |
dc.citation.endPage | 265 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | TRANSITIONAL-CELL CARCINOMA | - |
dc.subject.keywordPlus | COLONY-STIMULATING FACTOR | - |
dc.subject.keywordPlus | THYMIDYLATE SYNTHASE | - |
dc.subject.keywordPlus | PLUS GEMCITABINE | - |
dc.subject.keywordPlus | G-CSF | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordPlus | METHOTREXATE | - |
dc.subject.keywordPlus | MULTICENTER | - |
dc.subject.keywordPlus | CARBOPLATIN | - |
dc.subject.keywordAuthor | urothelial carcinoma | - |
dc.subject.keywordAuthor | bladder cancer | - |
dc.subject.keywordAuthor | pemetrexed | - |
dc.subject.keywordAuthor | cisplatin | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.